Akebia Therapeutics Inc. [AKBA] stock prices are up 1.30% to $1.56 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AKBA shares have gain 4.70% over the last week, with a monthly amount glided 8.33%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 110,000 shares of Akebia’s common stock on March 28, 2024, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on August 28, 2023, and kept the price target unchanged to $3.75. On May 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on March 31, 2022. Needham downgraded its rating to a Hold. Mizuho downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $10 to $2.
The stock price of Akebia Therapeutics Inc. [AKBA] has been fluctuating between $0.53 and $2.48 over the past year. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc. [NASDAQ: AKBA] shares were valued at $1.56 at the most recent close of the market. An investor can expect a potential return of 316.67% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
The Akebia Therapeutics Inc. [NASDAQ:AKBA] reported sales of 194.75M for trailing twelve months, representing a surge of 2.06%. Gross Profit Margin for this corporation currently stands at 0.62% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is 1.5 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5133 points at the first support level, and at 1.4667 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6133, and for the 2nd resistance point, it is at 1.6667.
Akebia Therapeutics Inc. [AKBA] reported earnings per share of $0 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.04/share, meaning a difference of $0.04 and a surprise factor of 100.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.08 per share as compared to estimates of -$0.08 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
It’s worth pointing out that Akebia Therapeutics Inc. [NASDAQ:AKBA]’s Current Ratio is 1.18. Also, the Quick Ratio is 1.03, while the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 1.68.
Transactions by insiders
Recent insider trading involved Butler John P., CEO and President, that happened on Feb 29 ’24 when 46570.0 shares were sold. SVP, Chief Operating Officer, Dahan Michel completed a deal on Feb 29 ’24 to sell 8661.0 shares. Meanwhile, SVP, Chief Medical Officer Burke Steven Keith sold 7169.0 shares on Feb 29 ’24.
